AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Heart Test Laboratories Raises $4.3 Million in Regulation A Offering, Issues Units and Converts Debt
ByAinvest
Thursday, Jul 31, 2025 1:22 pm ET1min read
Heart Test Laboratories has raised $4.3 million through its Regulation A Offering, issuing 1,241,188 Units. Additionally, the company completed a debt exchange, converting $1,105,000 of an unsecured promissory note into 301,111 shares of common stock. The total number of shares of common stock outstanding is now 2,244,247. The stock has a Buy rating with a $12.00 price target.
HeartSciences Inc. (HSCS), a leader in AI-powered cardiac diagnostics, recently reported its fiscal 2025 financial results and business updates, highlighting significant progress in its AI-ECG technology. The company's flagship MyoVista Insights™ cloud-native software platform, launched in May 2025, aims to modernize ECG management systems and serve as a marketplace for AI-ECG algorithms.Key financial highlights include:
- Cash on hand as of April 30, 2025, stood at $1.1 million.
- The company raised $3.1 million through a Reg A+ offering.
- $0.9 million of debt was converted to equity.
Business developments include:
- CMS approval for AI-ECG algorithm reimbursement at $128 per test.
- FDA Breakthrough Device designation for the aortic stenosis algorithm.
- Expansion to 44 granted patents worldwide.
- Preparation for FDA 510(k) submission of the MyoVista wavECG™ device.
HeartSciences also announced a partnership with Westcliffe Health Innovations in the UK, marking the first commercial customer for MyoVista Insights™. The platform is designed to be vendor- and device-agnostic, capable of running AI-ECG algorithm models from multiple partners. This partnership aims to enhance clinical decision-making and improve healthcare IT efficiency.
In addition, the company has strengthened its Scientific Advisory Board with the addition of three distinguished experts in cardiology and AI. These appointments align with HeartSciences' mission to transform ECG technology through AI for earlier heart disease detection.
The company's CEO, Andrew Simpson, will present at the Emerging Growth Conference 82 on May 21, 2025, providing investors with insights into the company's AI-ECG platform and mission.
References:
[1] https://www.stocktitan.net/news/HSCS/
[2] https://www.stocktitan.net/news/HSCS/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet